-+ 0.00%
-+ 0.00%
-+ 0.00%

AN2 Therapeutics grants CMO Cameron Trenor options for 233,333 shares at USD 5.36 each

PUBT·09/16/2026 21:46:51
Listen to the news
AN2 Therapeutics grants CMO Cameron Trenor options for 233,333 shares at USD 5.36 each
  • AN2 Therapeutics set inducement equity awards for new Chief Medical Officer Cameron Trenor with a Sept. 15, 2026 grant date.
  • Package includes a non-qualified stock option for 233,333 shares priced at USD 5.36, equal to the closing share price.
  • Option runs 10 years; 25% vests Aug. 24, 2026, with the remaining shares vesting monthly over three years.
  • Also granted 116,667 restricted stock units; 10,400 vest Jan. 1, 2027, with the balance vesting in three annual installments from Jan. 1, 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609161733BIZWIRE_USPR_____20260916_BW973446) on September 16, 2026, and is solely responsible for the information contained therein.